BMI View: Despite Netherlands' expectations for a return to positive economic growth in 2014, its
government will continue with austerity measures to comply with EU budget criteria. Drugmakers have
generally charged what the market will bear in both developed and emer ..."
BMI View: We anticipate further restrictions to medicine prices in 2014 under the Medicines Prices Act,
which will subdue the outlook for both patented and generic drugmakers in the country. This comes despite
expectations for a return to positive economic growth in 2 ..."
BMI View: As a result of the high and increasing average age in the Netherlands, our outlook for
healthcare expenditure in the country is broadly positive. On the other hand, we maintain that the
pharmaceutical sector in the Netherlands will not see a return to positi ..."
BMI View: We maintain our subdued outlook on the Dutch pharmaceutical and healthcare sector for the
remainder of 2013 and looking forward into 2014. With further essential structural reform to the public
sector on the horizon, leading to excessive budget deficits, we see econom ..."
BMI View: We continue to expect yet another year of pharmaceutical market value contraction in the
Netherlands. Having been valued at EUR6.56bn (US$8.33bn) at consumer prices in 2012, or US$498 per
capita, we expect negative pressures on volume consumption of medicines as well ..."
BMI View: While the recently proposed healthcare cost-containment measures in the Netherlands do not include price cuts on medicines, we believe measures such as increased health insurance premiums will act as market access barriers, creating a business environment that ultimatel ..."
While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which w ..."